PSD-95 Antibodies: Ushering in a New Era of Neuroprotection for Ischemic Stroke Treatment

1. Literature Information

Research Focus: Investigation of PSD-95 (Postsynaptic Density Protein-95) as a therapeutic target for ischemic stroke, the neuroprotective mechanism of PSD-95 inhibitors, and clinical efficacy of the peptide inhibitor Nerinetide (NA-1) through the ESCAPE-NA1 Phase III trial.

Core Innovation: Validation of PSD-95/nNOS interaction inhibition as a precise neuroprotective strategy, with Nerinetide demonstrating significant functional recovery and extended treatment window in ischemic stroke patients not receiving alteplase—transforming stroke therapy from vascular recanalization alone to "recanalization + neuroprotection."

2. Research Background

Ischemic stroke is the world’s leading cause of neurological disability, presenting formidable clinical challenges. The gold-standard treatment, alteplase (thrombolytic therapy), has a narrow therapeutic window (≤4.5 hours), carries high bleeding risks, and is only applicable to a small subset of patients. Moreover, reperfusion after thrombolysis or endovascular thrombectomy (EVT) can trigger secondary injuries such as oxidative stress and excitotoxicity, leading to irreversible neuronal damage. There is an urgent need for targeted neuroprotective drugs that extend the treatment window, reduce neuronal death, and complement recanalization therapies. PSD-95, a scaffolding protein critical for excitotoxic signaling, has emerged as a promising target—its inhibition interrupts neurotoxic pathways while preserving normal neuronal function, offering a new direction for stroke treatment.

3. Research Approaches

To advance PSD-95-targeted stroke therapy, the research team adopted a mechanism-to-clinic translational strategy:

1. Mechanistic Validation: Investigating the role of PSD-95 in excitotoxicity—specifically its interaction with NMDA receptors and nNOS—using biochemical, cellular, and animal models of ischemic stroke.
2. Preclinical Development: Optimizing PSD-95 inhibitors (e.g., Nerinetide) to block PSD-95/nNOS coupling while preserving NMDA receptor physiological function.
3. Clinical Trial Design: Conducting the multicenter, randomized, double-blind, placebo-controlled ESCAPE-NA1 Phase III trial (1,105 patients across 48 centers) to evaluate Nerinetide in acute ischemic stroke patients undergoing EVT.
4. Subgroup Analysis: Pre-specifying subgroups based on alteplase use (received vs. not received) to address the hypothesis that alteplase-activated plasmin degrades Nerinetide.
5. Efficacy Assessment: Measuring primary endpoints (functional independence via modified Rankin Scale [mRS] 0-2 at 90 days) and secondary endpoints (neurological deficits, mortality, infarct volume via MRI).

4. Research Outcomes

4.1 Neuroprotective Mechanism of PSD-95 Inhibitors

Under ischemic stress, excessive glutamate release activates NMDA receptors, which form a complex with PSD-95 and neuronal nitric oxide synthase (nNOS). This coupling triggers massive production of nitric oxide (NO), leading to neuronal apoptosis via nitrosative stress, mitochondrial dysfunction, and DNA damage. PSD-95 inhibitors (e.g., Nerinetide) specifically block the PSD-95/nNOS interaction, interrupting the neurotoxic signaling pathway without compromising normal NMDA receptor function—enabling precise neuroprotection.

4.2 Innovative Design of the ESCAPE-NA1 Trial

• Trial Design: Multicenter, randomized, double-blind, placebo-controlled study enrolling acute ischemic stroke patients undergoing EVT.
• Subgroup Stratification: Pre-specified analysis of patients who received alteplase vs. those who did not—based on preclinical evidence that alteplase-activated plasmin degrades Nerinetide.
• Endpoints: Primary endpoint (mRS 0-2 at 90 days); secondary endpoints (neurological function, mortality, infarct volume).

4.3 Clinical Efficacy of Nerinetide

In the subgroup of patients not receiving alteplase, Nerinetide demonstrated remarkable benefits:

• Functional Recovery: 59.4% of treated patients achieved functional independence (mRS 0-2), compared to 49.8% in the placebo group (19.3% relative improvement).
• Survival Advantage: 40% reduction in all-cause mortality, confirming robust neuroprotective effects.
• Imaging Validation: MRI showed a 22% reduction in cerebral infarct volume, providing objective biological evidence of efficacy.
• Extended Treatment Window: Maintained efficacy when administered within 12 hours of stroke onset—significantly expanding eligible patient populations.

Notably, no significant benefit was observed in patients receiving concurrent alteplase, validating the plasmin-mediated degradation hypothesis.

4.4 Clinical Significance of PSD-95 Inhibitors

• Therapeutic Paradigm Shift: Moving from "recanalization alone" to "recanalization + neuroprotection" for comprehensive stroke treatment.
• Extended Treatment Window: Extending effective intervention to 12 hours, addressing unmet needs for patients ineligible for early thrombolysis.
• Precision Medicine: Enabling patient stratification (based on alteplase use) to deliver personalized therapy.
• Mechanistic Validation: First human confirmation that the PSD-95/nNOS pathway is a viable therapeutic target for ischemic stroke.

4.5 Future Research Directions

• Dosing Optimization: Exploring sequential regimens (e.g., Nerinetide administered before alteplase during ambulance transport, as in the FRONTIER trial).
• Patient Selection: Developing rapid diagnostic tools to identify subgroups most likely to benefit from PSD-95 inhibitors.
• Combination Therapy: Investigating synergies with other neuroprotective agents or EVT.
• Indication Expansion: Evaluating potential efficacy in traumatic brain injury, subarachnoid hemorrhage, and other acute neurological injuries.

5. Product Empowerment by ANT BIO PTE. LTD.

ANT BIO PTE. LTD.’s STARTER brand, a leader in neuroscience antibodies, provides a critical tool for PSD-95 research: the "PSD-95 Recombinant Rabbit Monoclonal Antibody" (Catalog Nos.: S0B0447, S0B1102). This high-performance antibody is engineered to support mechanism research, preclinical development, and drug evaluation for ischemic stroke.

Key Roles of the Product:

1. Mechanistic Research: Enables visualization and quantification of PSD-95 expression and localization in brain tissues/cultured neurons—critical for validating PSD-95/nNOS coupling in ischemic models.
2. Preclinical Drug Development: Supports assessment of PSD-95 inhibitor efficacy (e.g., Nerinetide) by monitoring PSD-95 interaction with nNOS or NMDA receptors via Western Blot (WB), immunohistochemistry (IHC), and immunofluorescence (IF).
3. Synaptic Function Analysis: Precisely labels excitatory synaptic structures, facilitating studies on synaptic plasticity, density, and morphology—key endpoints for neuroprotective drug evaluation.
4. Reliable Performance: High specificity (minimal background), precise postsynaptic localization, and batch consistency ensure reproducible results across preclinical and translational studies.

The antibody is also valuable for research in Alzheimer’s disease, autism spectrum disorders, and schizophrenia—expanding its utility beyond stroke to broader neuroscience applications.

6. Brand Mission

ANT BIO PTE. LTD. is dedicated to empowering global life science advancement through three specialized sub-brands: ABSIN (general reagents, ELISA kits), STARTER (antibodies), and UA (recombinant proteins). Leveraging advanced development platforms—including recombinant rabbit/mouse monoclonal antibody generation, rapid antibody development, recombinant protein expression (E.coli, CHO, HEK293, Insect Cells), One-Step ELISA, and PTM Pan-Modification Antibody platforms—we deliver high-quality, compliant products certified by EU 98/79/EC, ISO9001, and ISO13485. Our mission is to partner with innovative pharmaceutical companies, research institutions, and scientists worldwide, providing innovative reagents and solutions that accelerate discoveries in neuroscience, cardiovascular medicine, and precision therapy.

7. Related Product List

8. AI Disclaimer

This article is AI-compiled and interpreted based on the original work. All intellectual property (e.g., images, data) of the original publication shall belong to the journal and the research team. For any infringement, please contact us promptly and we will take immediate action.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.